
Robson Q Monteiro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4913994/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Atazanavir Is a Competitive Inhibitor of SARS-CoV-2 Mpro, Impairing Variants Replication In Vitro and In Vivo. Pharmaceuticals, 2022, 15, 21.	3.8	21
2	Platelet-monocyte interaction amplifies thromboinflammation through tissue factor signaling in COVID-19. Blood Advances, 2022, 6, 5085-5099.	5.2	32
3	Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way. Journal of Molecular Cell Biology, 2022, 14, .	3.3	7
4	Ectophosphatase activity in the tripleâ€negative breast cancer cell line MDAâ€MBâ€231. Cell Biology International, 2021, 45, 411-421.	3.0	5
5	Recombinant human DNase I for the treatment of cancer-associated thrombosis: A pre-clinical study. Thrombosis Research, 2021, 203, 131-137.	1.7	20
6	Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia following ChAdOx1 nCOVID-19 vaccine in a pregnant woman. Haematologica, 2021, 106, 3025-3028.	3.5	10
7	Epidermal growth factor receptor regulates fibrinolytic pathway elements in cervical cancer: functional and prognostic implications. Brazilian Journal of Medical and Biological Research, 2021, 54, e10754.	1.5	2
8	Fundamentals in Covid-19-Associated Thrombosis: Molecular and Cellular Aspects. Frontiers in Cardiovascular Medicine, 2021, 8, 785738.	2.4	20
9	Characterization and internalization of small extracellular vesicles released by human primary macrophages derived from circulating monocytes. PLoS ONE, 2020, 15, e0237795.	2.5	16
10	Extracellular vesicle fingerprinting: the next generation for cancer diagnosis?. Signal Transduction and Targeted Therapy, 2020, 5, 263.	17.1	4
11	Development of 1311-ixolaris as a theranostic agent: metastatic melanoma preclinical studies. Clinical and Experimental Metastasis, 2020, 37, 489-497.	3.3	3
12	Neutrophil Extracellular Traps (NETs) Promote Pro-Metastatic Phenotype in Human Breast Cancer Cells through Epithelial–Mesenchymal Transition. Cancers, 2020, 12, 1542.	3.7	77
13	β-Lapachone enhances the antifungal activity of fluconazole against a Pdr5p-mediated resistant Saccharomyces cerevisiae strain. Brazilian Journal of Microbiology, 2020, 51, 1051-1060.	2.0	9
14	Pisum sativum Defensin 1 Eradicates Mouse Metastatic Lung Nodules from B16F10 Melanoma Cells. International Journal of Molecular Sciences, 2020, 21, 2662.	4.1	6
15	Cellular and Molecular Immunology Approaches for the Development of Immunotherapies against the New Coronavirus (SARS-CoV-2): Challenges to Near-Future Breakthroughs. Journal of Immunology Research, 2020, 2020, 1-21.	2.2	6
16	Interplay Between EGFR and the Platelet-Activating Factor/PAF Receptor Signaling Axis Mediates Aggressive Behavior of Cervical Cancer. Frontiers in Oncology, 2020, 10, 557280.	2.8	13
17	Novel Aspects of Extracellular Vesicles as Mediators of Cancer-Associated Thrombosis. Cells, 2019, 8, 716.	4.1	39
18	IL-1β Blockade Attenuates Thrombosis in a Neutrophil Extracellular Trap-Dependent Breast Cancer Model. Frontiers in Immunology, 2019, 10, 2088.	4.8	69

#	Article	IF	CITATIONS
19	NMR structure determination of Ixolaris and factor X(a) interaction reveals a noncanonical mechanism of Kunitz inhibition. Blood, 2019, 134, 699-708.	1.4	10
20	Oral Route Driven Acute Trypanosoma cruzi Infection Unravels an IL-6 Dependent Hemostatic Derangement. Frontiers in Immunology, 2019, 10, 1073.	4.8	14
21	H+-dependent inorganic phosphate transporter in breast cancer cells: Possible functions in the tumor microenvironment. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2180-2188.	3.8	18
22	Ixonnexin from Tick Saliva Promotes Fibrinolysis by Interacting with Plasminogen and Tissue-Type Plasminogen Activator, and Prevents Arterial Thrombosis. Scientific Reports, 2018, 8, 4806.	3.3	24
23	TR47, a PAR1-based peptide, inhibits melanoma cell migration inÂvitro and metastasis inÂvivo. Biochemical and Biophysical Research Communications, 2018, 495, 1300-1304.	2.1	7
24	Positive crosstalk between EGFR and the TF-PAR2 pathway mediates resistance to cisplatin and poor survival in cervical cancer. Oncotarget, 2018, 9, 30594-30609.	1.8	37
25	Pyrazolyl-Tetrazoles and Imidazolyl-Pyrazoles as Potential Anticoagulants and their Integrated Multiplex Analysis Virtual Screening. Journal of the Brazilian Chemical Society, 2018, , .	0.6	2
26	Protease-activated receptor 2 (PAR2) upregulates granulocyte colony stimulating factor (G-CSF) expression in breast cancer cells. Biochemical and Biophysical Research Communications, 2018, 504, 270-276.	2.1	15
27	Tissue factor mediates microvesicles shedding from MDA-MB-231 breast cancer cells. Biochemical and Biophysical Research Communications, 2018, 502, 137-144.	2.1	13
28	Inorganic phosphate transporters in cancer: Functions, molecular mechanisms and possible clinical applications. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1870, 291-298.	7.4	27
29	Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia. Experimental Hematology, 2018, 66, 50-62.	0.4	4
30	Blood coagulation abnormalities in multibacillary leprosy patients. PLoS Neglected Tropical Diseases, 2018, 12, e0006214.	3.0	14
31	Characterization of inorganic phosphate transport in the triple-negative breast cancer cell line, MDA-MB-231. PLoS ONE, 2018, 13, e0191270.	2.5	16
32	Breast-cancer extracellular vesicles induce platelet activation and aggregation by tissue factor-independent and -dependent mechanisms. Thrombosis Research, 2017, 159, 24-32.	1.7	65
33	1H, 15N and 13C resonance assignments of Ixolaris, a tissue factor pathway inhibitor from the tick salivary gland. Biomolecular NMR Assignments, 2017, 11, 293-296.	0.8	2
34	Recombinant expression of Ixolaris, a Kunitz-type inhibitor from the tick salivary gland, for NMR studies. Protein Expression and Purification, 2017, 139, 49-56.	1.3	2
35	Tumor-Derived Exosomes Induce the Formation of Neutrophil Extracellular Traps: Implications For The Establishment of Cancer-Associated Thrombosis. Scientific Reports, 2017, 7, 6438.	3.3	192
36	In Vitro Mode of Action and Anti-thrombotic Activity of Boophilin, a Multifunctional Kunitz Protease Inhibitor from the Midgut of a Tick Vector of Babesiosis, Rhipicephalus microplus. PLoS Neglected Tropical Diseases, 2016, 10, e0004298.	3.0	30

#	Article	IF	CITATIONS
37	Exploiting the antithrombotic effect of the (pro)thrombin inhibitor bothrojaracin. Toxicon, 2016, 119, 46-51.	1.6	12
38	Evoking picomolar binding in RNA by a single phosphorodithioate linkage. Nucleic Acids Research, 2016, 44, 8052-8064.	14.5	94
39	Hypoxia regulates the expression of tissue factor pathway signaling elements in a rat glioma model. Oncology Letters, 2016, 12, 315-322.	1.8	24
40	Protease-activated receptor 1 (PAR1): a promising target for the treatment of glioblastoma?. Translational Cancer Research, 2016, 5, S1274-S1280.	1.0	6
41	Identification and Mechanistic Analysis of a Novel Tick-Derived Inhibitor of Thrombin. PLoS ONE, 2015, 10, e0133991.	2.5	35
42	Thrombocytopenia in Dengue: Interrelationship between Virus and the Imbalance between Coagulation and Fibrinolysis and Inflammatory Mediators. Mediators of Inflammation, 2015, 2015, 1-16.	3.0	140
43	99mTc-ixolaris targets glioblastoma-associated tissue factor: In vitro and pre-clinical applications. Thrombosis Research, 2015, 136, 432-439.	1.7	9
44	Salivary Thromboxane A2-Binding Proteins from Triatomine Vectors of Chagas Disease Inhibit Platelet-Mediated Neutrophil Extracellular Traps (NETs) Formation and Arterial Thrombosis. PLoS Neglected Tropical Diseases, 2015, 9, e0003869.	3.0	16
45	Structural and Functional Analysis of a Platelet-Activating Lysophosphatidylcholine of Trypanosoma cruzi. PLoS Neglected Tropical Diseases, 2014, 8, e3077.	3.0	37
46	Plasmodium falciparum Infection Induces Expression of a Mosquito Salivary Protein (Agaphelin) That Targets Neutrophil Function and Inhibits Thrombosis without Impairing Hemostasis. PLoS Pathogens, 2014, 10, e1004338.	4.7	31
47	Thrombomodulin modulates cell migration in human melanoma cell lines. Melanoma Research, 2014, 24, 11-19.	1.2	10
48	Expression of tissue factor signaling pathway elements correlates with the production of vascular endothelial growth factor and interleukin-8 in human astrocytoma patients. Oncology Reports, 2014, 31, 679-686.	2.6	23
49	Intercellular transfer of tissue factor via the uptake of tumor-derived microvesicles. Thrombosis Research, 2013, 132, 450-456.	1.7	45
50	Structural Basis for the Interaction of Human β-Defensin 6 and Its Putative Chemokine Receptor CCR2 and Breast Cancer Microvesicles. Journal of Molecular Biology, 2013, 425, 4479-4495.	4.2	29
51	Desmolaris, a novel factor XIa anticoagulant from the salivary gland of the vampire bat (Desmodus) Tj ETQq1 1	0.784314 1.4	rgB <u>T</u> /Overlo
52	Aegyptin inhibits collagen-induced coagulation activation in vitro and thromboembolism in vivo. Biochemical and Biophysical Research Communications, 2013, 436, 235-239.	2.1	14
53	Activation of blood coagulation in cancer: implications for tumour progression. Bioscience Reports, 2013, 33, .	2.4	158
54	Leishmania amazonensis exhibits phosphatidylserine-dependent procoagulant activity, a process that is counteracted by sandfly saliva. Memorias Do Instituto Oswaldo Cruz, 2013, 108, 679-685.	1.6	11

#	Article	IF	CITATIONS
55	Lufaxin, a Novel Factor Xa Inhibitor From the Salivary Gland of the Sand Fly <i>Lutzomyia longipalpis</i> Blocks Protease-Activated Receptor 2 Activation and Inhibits Inflammation and Thrombosis In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2185-2198.	2.4	62
56	The tickâ€derived inhibitor Ixolaris prevents tissue factor signaling on tumor cells. Journal of Thrombosis and Haemostasis, 2012, 10, 1849-1858.	3.8	36
57	Protease-activated receptor-2 (PAR2) mediates VEGF production through the ERK1/2 pathway in human glioblastoma cell lines. Thrombosis Research, 2012, 129, S190-S191.	1.7	0
58	Defibrotide Interferes With Several Steps of the Coagulation-Inflammation Cycle and Exhibits Therapeutic Potential to Treat Severe Malaria. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 786-798.	2.4	29
59	Allosteric activation of human α-thrombin through exosite 2 by suramin analogs. Archives of Biochemistry and Biophysics, 2012, 520, 36-41.	3.0	1
60	Protease-activated receptor-2 (PAR2) mediates VEGF production through the ERK1/2 pathway in human glioblastoma cell lines. Biochemical and Biophysical Research Communications, 2012, 421, 221-227.	2.1	38
61	Inhibition of tissue factor by ixolaris reduces primary tumor growth and experimental metastasis in a murine model of melanoma. Thrombosis Research, 2012, 130, e163-e170.	1.7	28
62	Glycoinositolphospholipids from Trypanosomatids Subvert Nitric Oxide Production in Rhodnius prolixus Salivary Glands. PLoS ONE, 2012, 7, e47285.	2.5	22
63	Increased expression of protease-activated receptor 1 (PAR-1) in human leukemias. Blood Cells, Molecules, and Diseases, 2011, 46, 230-234.	1.4	17
64	Tissue factor as a target for the treatment of disseminated intravascular coagulation. Thrombosis Research, 2011, 127, 495-496.	1.7	3
65	Alboserpin, a Factor Xa Inhibitor from the Mosquito Vector of Yellow Fever, Binds Heparin and Membrane Phospholipids and Exhibits Antithrombotic Activity. Journal of Biological Chemistry, 2011, 286, 27998-28010.	3.4	62
66	Malignant transformation in melanocytes is associated with increased production of procoagulant microvesicles. Thrombosis and Haemostasis, 2011, 106, 712-723.	3.4	50
67	Structure and Behavior of Human α-Thrombin upon Ligand Recognition: Thermodynamic and Molecular Dynamics Studies. PLoS ONE, 2011, 6, e24735.	2.5	8
68	Venous thrombosis risk: Effects of palm oil and hydrogenated fat diet in rats. Nutrition, 2011, 27, 233-238.	2.4	9
69	Platelet Activating Factor Blocks Interkinetic Nuclear Migration in Retinal Progenitors through an Arrest of the Cell Cycle at the S/G2 Transition. PLoS ONE, 2011, 6, e16058.	2.5	14
70	Aegyptin displays highâ€ a ffinity for the von Willebrand factor binding site (RGQOGVMGF) in collagen and inhibits carotid thrombus formation <i>in vivo</i> . FEBS Journal, 2010, 277, 413-427.	4.7	42
71	Increased expression of tissue factor and protease-activated receptor-1 does not correlate with thrombosis in human lung adenocarcinoma. Brazilian Journal of Medical and Biological Research, 2010, 43, 403-408.	1.5	17
72	Nitrophorin 2, a factor IX(a)-directed anticoagulant, inhibits arterial thrombosis without impairing haemostasis. Thrombosis and Haemostasis, 2010, 104, 1116-1123.	3.4	27

#	Article	IF	CITATIONS
73	Tissue factor expression on monocytes from patients with severe dengue fever. Blood Cells, Molecules, and Diseases, 2010, 45, 334-335.	1.4	8
74	Hematophagy and Inhibition of the Extrinsic and Intrinsic Tenase Complexes. , 2010, , 219-237.		1
75	Nitrophorin 2, a factor IX(a)-directed anticoagulant, inhibits arterial thrombosis without impairing haemostasis. Thrombosis and Haemostasis, 2010, 104, 1116-23.	3.4	16
76	Anticoagulant activity of a sulfated galactan: Serpin-independent effect and specific interaction with factor Xa. Thrombosis and Haemostasis, 2009, 102, 1183-1193.	3.4	27
77	Lung adenocarcinoma and antiphospholipid antibodies. Autoimmunity Reviews, 2009, 8, 529-532.	5.8	12
78	Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model. Journal of Thrombosis and Haemostasis, 2009, 7, 1855-1864.	3.8	73
79	Structural and thermodynamic analysis of thrombin:suramin interaction in solution and crystal phases. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2009, 1794, 873-881.	2.3	21
80	Tumor-derived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserine-dependent manner. Cancer Letters, 2009, 283, 168-175.	7.2	214
81	Simultaneous tissue factor expression and phosphatidylserine exposure account for the highly procoagulant pattern of melanoma cell lines. Melanoma Research, 2009, 19, 301-308.	1.2	43
82	Evidence for increased expression of tissue factor and protease-activated receptor-1 in human esophageal cancer. Oncology Reports, 2009, 21, 1599-604.	2.6	21
83	Blood Coagulation, Inflammation, and Malaria. Microcirculation, 2008, 15, 81-107.	1.8	170
84	Prothrombin fragments containing kringle domains induce migration and activation of human neutrophils. International Journal of Biochemistry and Cell Biology, 2008, 40, 517-529.	2.8	4
85	Sulfated galactan is a catalyst of antithrombin-mediated inactivation of α-thrombin. Biochimica Et Biophysica Acta - General Subjects, 2008, 1780, 1047-1053.	2.4	9
86	Adenovirus Serotype 5 Hexon Mediates Liver Gene Transfer. Cell, 2008, 132, 397-409.	28.9	573
87	Serpin-independent anticoagulant activity of a fucosylated chondroitin sulfate. Thrombosis and Haemostasis, 2008, 100, 420-428.	3.4	61
88	Procoagulant properties of human MV3 melanoma cells. Brazilian Journal of Medical and Biological Research, 2008, 41, 99-105.	1.5	6
89	Serpin-independent anticoagulant activity of a fucosylated chondroitin sulfate. Thrombosis and Haemostasis, 2008, 100, 420-8.	3.4	21
90	Suramin counteracts the haemostatic disturbances produced by Bothrops jararaca snake venom. Toxicon, 2007, 49, 931-938.	1.6	12

#	Article	IF	CITATIONS
91	Plasmodium falciparum-infected erythrocytes induce tissue factor expression in endothelial cells and support the assembly of multimolecular coagulation complexes. Journal of Thrombosis and Haemostasis, 2007, 5, 155-165.	3.8	84
92	Ixolaris binding to factor X reveals a precursor state of factor Xa heparin-binding exosite. Protein Science, 2007, 17, 146-153.	7.6	42
93	Correlation of Thrombosis and Prothrombotic Markers with Outcome in Lung Adenocarcinoma Patients: A Prospective Study Blood, 2007, 110, 3985-3985.	1.4	1
94	Ecotin modulates thrombin activity through exosite-2 interactions. International Journal of Biochemistry and Cell Biology, 2006, 38, 1893-1900.	2.8	5
95	Antithrombotic properties of Ixolaris, a potent inhibitor of the extrinsic pathway of the coagulation cascade. Thrombosis and Haemostasis, 2006, 96, 7-13.	3.4	60
96	On the molecular mechanisms for the highly procoagulant pattern of C6 glioma cells. Journal of Thrombosis and Haemostasis, 2006, 4, 1546-1552.	3.8	40
97	Counteracting effect of glycyrrhizin on the hemostatic abnormalities induced by Bothrops jararaca snake venom. British Journal of Pharmacology, 2006, 148, 807-813.	5.4	25
98	Platelet-activating factor-like activity isolated from Trypanosoma cruzi. International Journal for Parasitology, 2006, 36, 165-173.	3.1	20
99	Ixolaris: a Factor Xa heparin-binding exosite inhibitor. Biochemical Journal, 2005, 387, 871-877.	3.7	65
100	Targeting exosites on blood coagulation proteases. Anais Da Academia Brasileira De Ciencias, 2005, 77, 275-280.	0.8	17
101	Bothrojaracin, a <i>Bothrops jararaca</i> Snake Venom-Derived (Pro)Thrombin Inhibitor, as an Anti-Thrombotic Molecule. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2005, 34, 160-163.	0.3	18
102	Assembly and regulation of prothrombinase complex on B16F10 melanoma cells. Thrombosis Research, 2005, 115, 123-129.	1.7	13
103	New insights into conformational and functional stability of human α-thrombin probed by high hydrostatic pressure. FEBS Journal, 2004, 271, 3580-3587.	0.2	14
104	Suramin interaction with human α-thrombin: inhibitory effects and binding studies. International Journal of Biochemistry and Cell Biology, 2004, 36, 2077-2085.	2.8	15
105	Subunit Dissociation, Unfolding, and Inactivation of Bothrojaracin, a C-Type Lectin-like Protein from Snake Venomâ€. Biochemistry, 2003, 42, 509-515.	2.5	11
106	Antithrombotic effect of Glycyrrhizin, a plant-derived thrombin inhibitor. Thrombosis Research, 2003, 112, 93-98.	1.7	80
107	Mechanisms of ouabain toxicity. FASEB Journal, 2003, 17, 1700-1702.	0.5	43
108	Lysophosphatidylcholine Acts as an Anti-hemostatic Molecule in the Saliva of the Blood-sucking Bug Rhodnius prolixus. Journal of Biological Chemistry, 2003, 278, 27766-27771.	3.4	35

#	Article	IF	CITATIONS
109	Bothrojaracin, a Proexosite I Ligand, Inhibits Factor Va-Accelerated Prothrombin Activation. Thrombosis and Haemostasis, 2002, 87, 288-293.	3.4	26
110	Bothrojaracin, a proexosite I ligand, inhibits factor Va-accelerated prothrombin activation. Thrombosis and Haemostasis, 2002, 87, 288-93.	3.4	9
111	Proteolytic action of Bothrops jararaca venom upon its own constituents. Toxicon, 2001, 39, 787-792.	1.6	26
112	Interaction of Bothrojaracin with Prothrombin. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2001, 31, 273-278.	0.3	7
113	Characterization of bothrojaracin interaction with human prothrombin. Protein Science, 2001, 10, 1897-1904.	7.6	27
114	Inhibition of Prothrombin Activation by Bothrojaracin, a C-Type Lectin from Bothrops jararaca Venom. Archives of Biochemistry and Biophysics, 2000, 382, 123-128.	3.0	17
115	Allosteric Changes of Thrombin Catalytic Site Induced by Interaction of Bothrojaracin with Anion-Binding Exosites I and II. Biochemical and Biophysical Research Communications, 1999, 262, 819-822.	2.1	25
116	Bothrops jararaca snakes produce several bothrojaracin isoforms following an individual pattern. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 1998, 120, 791-798.	1.6	14
117	Variability of bothrojaracin isoforms and other venom principles in individual jararaca (Bothrops) Tj ETQq1 1 0.784	1314 rgBT 1.6	$ Q_2$ verlock 1
118	Identification of Glycyrrhizin as a Thrombin Inhibitor. Biochemical and Biophysical Research Communications, 1997, 235, 259-263.	2.1	82
119	Distinct bothrojaracin isoforms produced by individual jararaca (Bothrops jararaca) snakes. Toxicon, 1997, 35, 649-657.	1.6	21